Intellia Therapeutics (NTLA) News Today → **Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (From Huge Alerts) (Ad) Free NTLA Stock Alerts $26.02 -0.20 (-0.76%) (As of 03:04 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 8:59 PM | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. cut its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,478,562 shares of the company's stockMay 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)May 14, 2024 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) PT Raised to $70.00 at BMO Capital MarketsMay 14, 2024 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 8.5% on Analyst UpgradeMay 13, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 8.5% After Analyst UpgradeIntellia Therapeutics (NASDAQ:NTLA) Trading 8.5% Higher on Analyst UpgradeMay 13, 2024 | seekingalpha.comIntellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene TherapiesMay 12, 2024 | finance.yahoo.comEarnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 12, 2024 | americanbankingnews.comCitigroup Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $29.00May 12, 2024 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Rating Increased to Sell at StockNews.comMay 11, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Raised to "Sell" at StockNews.comStockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a research report on Friday.May 10, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $29.00 at CitigroupCitigroup cut their price target on Intellia Therapeutics from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Friday.May 10, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)May 10, 2024 | marketbeat.comBMO Capital Markets Raises Intellia Therapeutics (NASDAQ:NTLA) Price Target to $70.00BMO Capital Markets lifted their target price on Intellia Therapeutics from $62.00 to $70.00 and gave the company an "outperform" rating in a report on Friday.May 10, 2024 | fool.comCathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)May 10, 2024 | finance.yahoo.comIntellia Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 9, 2024 | msn.comNTLA Stock Earnings: Intellia Therapeutics Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Up to $23.00Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up to $23.00May 9, 2024 | finanznachrichten.deIntellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 9, 2024 | seekingalpha.comCrispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing IcebergMay 9, 2024 | globenewswire.comIntellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 5, 2024 | marketbeat.com265,981 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by Vestmark Advisory Solutions Inc.Vestmark Advisory Solutions Inc. bought a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 265,981 shares of the company's stock, valued at approximately $8,110,000. VestMay 3, 2024 | investorplace.comShhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's RadarMay 3, 2024 | marketbeat.comIntellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on ThursdayIntellia Therapeutics (NASDAQ:NTLA) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.May 3, 2024 | investing.comIntellia Therapeutics Inc (NTLA) Earnings Dates & ReportsMay 2, 2024 | finance.yahoo.comIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company UpdatesMay 2, 2024 | globenewswire.comIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company UpdatesMay 2, 2024 | investorplace.com3 Gene Editing Stocks with the Potential to Make You an Overnight MillionaireApril 30, 2024 | seekingalpha.comInvest In A Revolutionary Gene Therapy With CRISPR TherapeuticsApril 29, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 6.8%Intellia Therapeutics (NASDAQ:NTLA) Shares Up 6.8%April 29, 2024 | globenewswire.comIntellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024April 28, 2024 | marketbeat.comabrdn plc Buys New Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)abrdn plc bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 154,269 shares of the company's stock, valued at approximately $4,704,000. abrdApril 27, 2024 | investing.comIntellia Therapeutics Inc (NTLA)April 25, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year Low at $19.77Intellia Therapeutics (NASDAQ:NTLA) Hits New 52-Week Low at $19.77April 25, 2024 | finance.yahoo.comIntellia (NTLA) to Report Q1 Earnings: What's in the Cards?April 23, 2024 | marketbeat.comIntellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at WedbushWedbush reaffirmed a "neutral" rating and set a $29.00 price objective on shares of Intellia Therapeutics in a report on Tuesday.April 20, 2024 | marketbeat.comFederated Hermes Inc. Increases Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Federated Hermes Inc. grew its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 13.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,016,300 shares of the company's stock after buying an additional 244,722April 17, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Sells 41,733 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Sumitomo Mitsui Trust Holdings Inc. lessened its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,478,562 shares of the coApril 15, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low at $22.51Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year Low at $22.51April 15, 2024 | marketbeat.comMirae Asset Global Investments Co. Ltd. Sells 100,885 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Mirae Asset Global Investments Co. Ltd. lowered its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 35.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 185,858 shares of the company's stoApril 13, 2024 | marketbeat.comCapital Advisors Inc. OK Acquires 73,379 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)Capital Advisors Inc. OK boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 34.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 284,738 shaApril 12, 2024 | fool.comCathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.April 9, 2024 | fool.comBull Market and Beyond: 3 Stocks Just Waiting to SoarApril 5, 2024 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the thirteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and nineApril 2, 2024 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 7.1% Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 7.1%March 28, 2024 | benzinga.comSmart Money Is Betting Big In NTLA OptionsMarch 28, 2024 | marketbeat.comARK Investment Management LLC Grows Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)ARK Investment Management LLC boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 14.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,412,449 shares of the company's stocMarch 28, 2024 | fool.comBetter Cathie Wood Stock: Moderna vs. IntelliaMarch 22, 2024 | marketwatch.comIntellia Therapeutics Ends Co-Development Agreement With RegeneronMarch 22, 2024 | msn.comIntellia opts out of hemophilia pact with Regeneron Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address **Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (Ad)Learn more about why Zack’s has increased its price target on this company to a whopping $23.25! Click for Zack's full report NTLA Media Mentions By Week NTLA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.350.42▲Average Medical News Sentiment NTLA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼54▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Celldex Therapeutics News Myriad Genetics News Neogen News QuidelOrtho News Editas Medicine News CRISPR Therapeutics News Cellectis News Sangamo Therapeutics News Lantheus News Janux Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsUrgent Nvidia WarningAltimetryThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
